在癌症治疗中准Acod1/itaconate:机制和机遇
Tianlin Deng1, Xiuyan Li2, Shuodong Wu1
1Department of General surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Pharmacological research
|February 15, 2026
概括
伊塔科纳酸是一种免疫代谢物,在癌症免疫中起着双重作用,影响瘤生长和免疫反应. 准Acod1/itaconate通路为癌症治疗提供了新的策略.
科学领域:
- 免疫代谢过程中的免疫代谢.
- 癌症生物学 癌症生物学
- 分子瘤学分子瘤学
背景情况:
- 由于瘤异质性,免疫抑制微环境和治疗耐药性,癌症存在重大临床挑战.
- 免疫代谢重编程是一个关键的研究领域,揭示了代谢物如何调节免疫反应.
- 由巨细胞合成的伊塔科纳酸,弥合了代谢压力和抗瘤免疫力.
研究的目的:
- 审查伊塔科纳酸在瘤微环境中的多方面的作用.
- 综合临床前证据关于itaconate及其衍生物在各种癌症系统.
- 巩固针对癌症治疗中的Acod1/itaconate途径的治疗策略.
主要方法:
- 科学文献的系统审查.
- 对伊塔康酸盐的演变和功能进行分析.
- 对伊塔康酸衍生物的临床前数据的综合.
- 巩固针对阿科德1/伊他康酸盐途径的治疗策略.
主要成果:
- 伊塔科纳酸具有双重作用,在瘤微环境中既有前瘤作用,也有反瘤作用.
- 临床前研究表明,伊塔科纳酸及其衍生物在各种瘤类型中的潜力.
- 新兴的战略重点是针对Acod1/itaconate途径进行增强癌症治疗.
结论:
- 伊塔科纳酸是一种关键的免疫代谢物,对癌症免疫有重大影响.
- 准Acod1/itaconate通路为新型癌症疗法提供了一个有希望的途径.
- 本综述提供了免疫代谢的见解,以克服癌症治疗的挑战.
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Inhibition of Cdk Activity
6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K


